We Can Kill COVID! Here's the Proof., page-20

First 20 Last

Share
Profile

Follow
Puttinfordough

585 Posts.

182

02/11/20

18:07

Post #: 48592350
Share

Originally posted by ozblue: ↑

@Puttinfordough ..."Did you not state only weeks ago that this technology could not be used in the same room as humans and this made it no different to any other FRG generator?"

If you actually read and quoted the post, I also added unless they could neutralize the high levels of free radicals that are unsafe for humans (or other life). Only after that did the company come out with some type of 'neutralizer' on their web page. It was a few months ago not weeks.

You obviously do not understand how the free radicals are generated and why other pulsed corona discharge units produce the SAME reactive oxygen species as the FRG unit, and have equal problems.

Currently the 'neutralizer' is just a word used by the company, they have not indicated they have anything that performs this role via announcement to the market, yet it appeared this year after it was obvious that the Bluegen unit as portrayed a couple of years ago, would put high levels of ozone into the air if the intake air was dry.

I get that shareholders don't want to see any problems with their investment, but please don't come back here in a year or so and state that you were uninformed about the tech.

If they do come up with a great neutralizer for the waste products from the FRG unit, then it will be very valuable and probably make the company, but the neutralizer will be the great tech, not the FRG.

Expand

Thanks for trying to save us all Oz. Sorry to be blunt. You talk crap. The tb trials were over 12 moths ago and involved the machine being in the same room as the patient. Nothing has changed. We were arguing you about this ad nauseum. We do not have the same problem as all other FRG technologies the company has also stated this. I would love to hear negatives if they are true. Yours are not and have been dispelled. It seems you want it to be an issue though. Why?

PO3 Price at posting: $1.75 Sentiment: Buy Disclosure: Held
4 Upvote

0 Great analysis

Reply

Top Stories

BPH

Australia’s gas crisis is here – and dying coal plants aren’t helping

BOE

Boss extends June win streak with boosted Alta Mesa extraction rates

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

'Not possible' to port renewable gas: ACCC takes AGN to court

OCC

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

ASX Market Close: Index creeps lower as half-year mark approaches | June 26

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

ASX Market Open: IPO hype, Wall Street ATHs push Aussies into green hope | June 27

SRL

Sunrise pops on top scandium hits NSW explorer will now use for 'multi-decade' plan

PAR

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

First 20 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

We Can Kill COVID! Here's the Proof., page-20

Top Stories

Australia’s gas crisis is here – and dying coal plants aren’t helping

Boss extends June win streak with boosted Alta Mesa extraction rates

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

'Not possible' to port renewable gas: ACCC takes AGN to court

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

ASX Market Close: Index creeps lower as half-year mark approaches | June 26

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

ASX Market Open: IPO hype, Wall Street ATHs push Aussies into green hope | June 27

Sunrise pops on top scandium hits NSW explorer will now use for 'multi-decade' plan

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

Featured News